EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Multizentrische Studie

DB-OTO Gene Therapy for Inherited Deafness

Vassili Valayannopoulos, Manohar Bance, Daniela S Carvalho iD, John H Greinwald, Steven A Harvey, Akira Ishiyama, Evie C Landry, Hubert Löwenheim, Lawrence R Lustig iD, Manuel Manrique, Robert Nash, Rubén Polo und 23 weitere

New England Journal of Medicine · 12.03.2026 · 394 (11) · 1074-1083

DOI: 10.1056/nejmoa2400521 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift New England Journal of Medicine, erschienen am 12.03.2026. Verfasst von Vassili Valayannopoulos und 34 weiteren Autor:innen. Beteiligte Einrichtung: Regeneron Pharmaceuticals, Tarrytown, NY. Hauptthemen laut MEDLINE: Deafness, Genetic Therapy, Membrane Proteins. Die Arbeit wurde bisher 78-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Regeneron Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DeafnessGenetic TherapyMembrane ProteinsAdolescentChild, PreschoolFemaleHumansMaleAudiometry, Pure-ToneAuditory ThresholdDependovirusGenetic VectorsDNA, ComplementarySynaptic TransmissionAcoustic StimulationTreatment OutcomePromoter Regions, GeneticHair Cells, Auditory, InnerInfant

Substanzen

Membrane ProteinsOTOF protein, humanDNA, Complementary

Autor:innen und Institutionen

  • Regeneron Pharmaceuticals, Tarrytown, NY.
  • University of Cambridge, Cambridge, United Kingdom.
  • Department of Otolaryngology Head and Neck Surgery, University of California, San Diego, La Jolla.
  • Cincinnati Children's Hospital, University of Cincinnati, Cincinnati.
  • Department of Otolaryngology and Communication Sciences, Medical College of Wisconsin, Wauwatosa.
  • UCLA School of Medicine, Los Angeles.

ORCID-Profile: Daniela S Carvalho, Lawrence R Lustig

Förderung

  • Regeneron Pharmaceuticals

Zitieren

APA

Valayannopoulos, V., Bance, M., Carvalho, D. S., Greinwald, J. H., Harvey, S. A., Ishiyama, A., Landry, E. C., Löwenheim, H., Lustig, L. R., Manrique, M., Nash, R., Polo, R., Pritchett, C. V., Rubinstein, J. T., Shearer, A. E., Del Castillo, I., Anderson, J. J., Corrales, C. E., Quigley, T. M., …, & CHORD Study Group (2026). DB-OTO Gene Therapy for Inherited Deafness. New England Journal of Medicine, 394(11), 1074-1083. https://doi.org/10.1056/nejmoa2400521

Vancouver

Valayannopoulos V, Bance M, Carvalho DS, Greinwald JH, Harvey SA, Ishiyama A, et al. DB-OTO Gene Therapy for Inherited Deafness. New England Journal of Medicine. 2026;394(11):1074-1083. doi:10.1056/nejmoa2400521

BibTeX
@article{Valayannopoulos2026,
  author = {Valayannopoulos, Vassili and Bance, Manohar and Carvalho, Daniela S and Greinwald, John H and Harvey, Steven A and Ishiyama, Akira and Landry, Evie C and Löwenheim, Hubert and Lustig, Lawrence R and Manrique, Manuel and Nash, Robert and Polo, Rubén and Pritchett, Cedric V and Rubinstein, Jay T and Shearer, A Eliot and Del Castillo, Ignacio and Anderson, Jeffery J and Corrales, C Eduardo and Quigley, Tera M and Riggs, William J and Weber, Peter and Wilson, Gary and Irvin, Susan C and Hassan, Hazem E and Chen, Yanping and Liu, Rong and Drummond, Meghan C and Sabin, Leah R and Musser, Bret J and Yancopoulos, George D and Kyratsous, Christos A and Herman, Gary A and Baras, Aris and Whitton, Jonathon P and CHORD Study Group, CHORD Study Group},
  title = {DB-OTO Gene Therapy for Inherited Deafness},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {11},
  pages = {1074--1083},
  doi = {10.1056/nejmoa2400521}
}
Kostenlos starten →